<SEC-DOCUMENT>0001157523-14-003467.txt : 20140812
<SEC-HEADER>0001157523-14-003467.hdr.sgml : 20140812
<ACCEPTANCE-DATETIME>20140812160522
ACCESSION NUMBER:		0001157523-14-003467
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20140812
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140812
DATE AS OF CHANGE:		20140812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD RESEARCH CORP
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21898
		FILM NUMBER:		141033996

	BUSINESS ADDRESS:	
		STREET 1:		225 SOUTH LAKE AVENUE
		STREET 2:		SUITE 1050
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101
		BUSINESS PHONE:		626-304-3400

	MAIL ADDRESS:	
		STREET 1:		225 SOUTH LAKE AVENUE
		STREET 2:		SUITE 1050
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a50923030.htm
<DESCRIPTION>ARROWHEAD RESEARCH CORP. 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2014 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <p style="text-align: center">
      <br>
      <br>
      <font style="font-family: Times New Roman; font-size: 18pt"><b>UNITED
      STATES</b></font><b><font style="font-family: Times New Roman; font-size: 18pt"><br style="font-family: Times New Roman; font-size: 18pt"></font><font style="font-family: Times New Roman; font-size: 18pt">SECURITIES
      AND EXCHANGE COMMISSION</font></b><br><font style="font-family: Times New Roman; font-size: 12pt"><b>WASHINGTON,
      D.C. 20549</b></font><br><br><font style="font-family: Times New Roman; font-size: 18pt"><b>FORM
      8-K</b></font><br><br><font style="font-family: Times New Roman; font-size: 12pt"><b>CURRENT
      REPORT</b></font><br><br><font style="font-family: Times New Roman; font-size: 12pt"><b>PURSUANT
      TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</b></font><br><br><font style="font-family: Times New Roman; font-size: 10pt">Date
      of Report (Date of earliest event reported): August 12, 2014</font><font style="font-family: Times New Roman; font-size: 10pt"><br style="font-family: Times New Roman; font-size: 10pt"></font><br><font style="font-family: Times New Roman; font-size: 16pt"><b>Arrowhead
      Research Corporation</b></font><br><font style="font-family: Times New Roman; font-size: 10pt">(Exact
      name of registrant as specified in its charter)</font><br><br>0-21898<br>(Commission
      File Number)<br><br>
    </p>
    <div style="text-align:center">
    <table style="margin-left:auto;margin-right:auto; font-family: Times New Roman; font-size: 10pt; margin-bottom: 10.0px; width: 100%" cellspacing="0">
      <tr>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; width: 50%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Delaware
          </p>
        </td>
        <td valign="bottom" style="padding-right: 0.0px; white-space: nowrap; text-align: center; padding-left: 0.0px; width: 50%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            46-0408024
          </p>
        </td>
      </tr>
      <tr>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; width: 50%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            (State or other jurisdiction of incorporation)
          </p>
        </td>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; width: 50%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            (IRS Employer Identification No.)
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="white-space: nowrap; text-align: center">

    </p>
    <p style="white-space: nowrap; text-align: center">
      225 South Lake Avenue, Suite 1050, Pasadena, CA&#160;&#160;91101<br>(Address
      of principal executive offices) (Zip Code)<br><br>Registrant's telephone
      number, including area code (626) 304-3400
    </p>
    <p style="text-align: center">

    </p>
    <p>

    </p>
    <p>
      <font style="font-family: Times New Roman; font-size: 10pt">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions:</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font>
    </p>
    <div style="margin-left: 0pt; margin-right: 0pt; text-indent: 0pt; margin-bottom: 10pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p>
      <b>Item 2.02. Results of Operations and Financial Condition.</b>
    </p>
    <p>
      On August 12, 2014, Arrowhead Research Corporation announced and
      commented on its fiscal 2014 third quarter financial results for the
      period ended June 30, 2014. A copy of the press release is furnished
      herewith as Exhibit&#160;99.1.
    </p>
    <p>
      <i>In accordance with General Instruction B.2 of Form 8-K, the
      information in this Current Report on Form 8-K, including Exhibit&#160;99.1,
      shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities
      Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise
      subject to the liabilities of that section, nor shall it be deemed
      incorporated by reference in any filing under the Securities Act of
      1933, as amended, or the Exchange Act, whether made before or after the
      date hereof, except as expressly set forth by specific reference in such
      filing to this Current Report on Form 8-K.</i>
    </p>
    <p>

    </p>
    <p>
      <b>Item 9.01. Financial Statements and Exhibits. </b>
    </p>
    <p>
      (d)&#160;Exhibits
    </p>
<div style="text-align:left">
    <table style="font-family: Times New Roman; font-size: 10pt; margin-bottom: 10.0px; width: 100%" cellspacing="0">
      <tr>
        <td valign="bottom" style="text-align: left; padding-left: 0.0px; width: 10%; border-bottom: solid black 1.0pt">
          <b>Exhibit No.</b>
        </td>
        <td valign="bottom" style="text-align: left; padding-left: 0.0px; padding-bottom: 2.0px; width: 5%">
          &#160;
        </td>
        <td valign="bottom" style="text-align: left; padding-left: 0.0px; width: 85%; border-bottom: solid black 1.0pt">
          <b>Description</b>
        </td>
      </tr>
      <tr>
        <td style="width: 10%">

        </td>
        <td style="width: 5%">

        </td>
        <td style="width: 85%">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-right: 0.0px; white-space: nowrap; text-align: left; padding-left: 0.0px; width: 10%">
          99.1
        </td>
        <td valign="bottom" style="text-align: left; padding-left: 0.0px; width: 5%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 85%">
          Press Release, dated August 12, 2014.
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="margin-left: 0pt; margin-right: 0pt; text-indent: 0pt; margin-bottom: 10pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt"><b>SIGNATURES</b></font>
    </p>
    <p>
      <font style="font-family: Times New Roman; font-size: 10pt">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned thereunto duly authorized.</font>
    </p>
<div style="text-align:left">
    <table style="font-family: Times New Roman; font-size: 10pt; margin-bottom: 10.0px; width: 100%" cellspacing="0">
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 6%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Date:
          </p>
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 44%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            August 12, 2014
          </p>
        </td>
        <td colspan="3" valign="top" style="text-align: left; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td colspan="3" valign="top" style="text-align: left; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            ARROWHEAD RESEARCH CORPORATION
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td style="width: 3%">

        </td>
        <td style="width: 5%">
          &#160;
        </td>
        <td style="width: 42%">

        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td style="width: 3%">

        </td>
        <td style="width: 5%">

        </td>
        <td style="width: 42%">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td style="width: 3%">

        </td>
        <td style="width: 5%">

        </td>
        <td style="width: 42%">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px; padding-bottom: 2.0px; width: 6%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; padding-bottom: 2.0px; width: 44%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; padding-bottom: 2.0px; width: 3%">
          By:
        </td>
        <td style="width: 5%; border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 42%; border-bottom: solid black 1.0pt">
          <p style="margin-bottom: 0px; margin-top: 0px">
            /s/ Kenneth Myszkowski
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td style="width: 3%">

        </td>
        <td style="width: 5%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 42%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Kenneth Myszkowski
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td style="width: 3%">

        </td>
        <td style="width: 5%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 42%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Chief Financial Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a50923030ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2014 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 8pt; font-family: Times New Roman">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 12pt"><b>Arrowhead
      Reports Fiscal 2014 Third Quarter Financial Results and Provides Update
      on ARC-520</b></font>
    </p>
    <p style="text-align: center">
      <i><font style="font-family: Times New Roman; font-size: 12pt"><b>-
      Conference Call Today at 4:30 p.m. EDT</b></font></i>
    </p>
    <p>
      PASADENA, Calif.--(BUSINESS WIRE)--August 12, 2014--Arrowhead Research
      Corporation (NASDAQ: ARWR), a biopharmaceutical company developing
      targeted RNAi therapeutics, today announced financial results for its
      fiscal 2014 third quarter ended June 30, 2014 and provided an update on
      the Phase 2a study of ARC-520, its RNAi-based candidate for the
      treatment of chronic hepatitis B infection. The company is hosting a
      conference call at 4:30 p.m. EDT to discuss results. Conference call and
      webcast details can be found below.
    </p>
    <p>
      <b>ARC-520 Phase 2a Study Update</b>
    </p>
    <ul>
      <li style="margin-bottom: 10.0px">
        Completed dosing of 1 mg/kg and 2 mg/kg dose cohorts
      </li>
      <li style="margin-bottom: 10.0px">
        Initial blinded data suggest that the magnitude of HBsAg knockdown is
        similar to non-human primate studies, including the chronically
        infected chimpanzee reported on previously
      </li>
      <li style="margin-bottom: 10.0px">
        Duration of knockdown appears to be substantially more sustained than
        in non-human primates, with patients in the 2 mg/kg group still
        demonstrating substantial knockdown after 8 weeks, which is the most
        recent time point available
      </li>
      <li style="margin-bottom: 10.0px">
        HBsAg levels appear to continue to decline in a number of patients at
        the 8 week time point in the 2 mg/kg group
      </li>
      <li style="margin-bottom: 10.0px">
        Based on initial review, dosing less frequent than once monthly will
        be explored in Phase 2b
      </li>
      <li style="margin-bottom: 10.0px">
        ARC-520 continues to be well tolerated, with no dropouts or serious
        adverse events reported
      </li>
      <li style="margin-bottom: 10.0px">
        The overall rate of AEs has been lower in the Phase 2a than in the
        Phase 1 normal volunteer study and safety labs continue to show no
        indication of end organ toxicity
      </li>
      <li style="margin-bottom: 10.0px">
        Enrolled and dosed additional subjects at 3 mg/kg in the still open
        normal volunteer study and the dose performed well, without detected
        differences from safety and tolerability results at the other doses.
        Overall AEs do not appear to be increasing in frequency or severity
        with dose
      </li>
      <li style="margin-bottom: 10.0px">
        Received IRB and DSMB approvals to proceed and began enrolling an
        additional dose cohort at 3 mg/kg in the Phase 2a patient study
      </li>
    </ul>
    <div style="margin-left: 0pt; margin-right: 0pt; margin-bottom: 10pt; text-indent: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>Fiscal 2014 Third Quarter and Recent Company Highlights</b>
    </p>
    <ul>
      <li style="margin-bottom: 10.0px">
        Nominated a second clinical candidate using our DPC delivery system,
        ARC-AAT, for the treatment of a rare liver disease associated with
        alpha-1 antitrypsin deficiency and hosted an analyst day to present
        preclinical data
      </li>
      <li style="margin-bottom: 10.0px">
        Signed an agreement with The Alpha-1 Project (TAP), the venture
        philanthropy subsidiary of the Alpha-1 Foundation. Under the terms of
        the agreement, TAP will partially fund the development of ARC-AAT. In
        addition, TAP will make its scientific advisors available to
        Arrowhead, assist with patient recruitment for clinical trials through
        the Alpha-1 Foundation Patient Research Registry, and engage in other
        collaborative efforts that support the development of ARC-AAT
      </li>
      <li style="margin-bottom: 10.0px">
        Initiated the final steps required to file an IND or equivalent
        application for ARC-AAT, including necessary toxicology studies
      </li>
      <li style="margin-bottom: 10.0px">
        Expanded intellectual property protection with U.S. Patent Application
        number 13/535,454 covering ARC-520's siRNA component, being recently
        allowed by the U.S. Patent and Trademark Office
      </li>
      <li style="margin-bottom: 10.0px">
        Presented data on advancements made to the DPC delivery system at
        multiple scientific meetings
      </li>
      <li style="margin-bottom: 10.0px">
        Arrowhead added to the broad-market Russell 3000 index and small-cap
        Russell 2000 index
      </li>
    </ul>
    <div style="margin-left: 0pt; margin-right: 0pt; text-indent: 0pt; margin-bottom: 10pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>Selected Fiscal 2014 Third Quarter Financial Results</b>
    </p>
    <p>
      Net loss attributable to Arrowhead for the quarter was $11.6 million, or
      $0.22 per share based on 51.9 million weighted average shares
      outstanding. This compares with a net loss attributable to Arrowhead of
      $6.1 million, or $0.23 per share based on 26.1 million weighted average
      shares outstanding, for the quarter ended June 30, 2013.
    </p>
    <p>
      Total operating expenses for the quarter were $12.7 million, compared to
      $6.4 million for the quarter ended June 30, 2013. Research and
      development related expenses were $6.4 million and general and
      administrative expenses were $1.6 during the quarter.
    </p>
    <p>
      Net cash used in operating activities for the first nine months of
      fiscal 2014 was $24.5 million, compared with $13.6 million in the prior
      year period.
    </p>
    <p>
      The company&#8217;s cash and investments of cash were $188.5 million at June
      30, 2014, compared to $29.8 million at September 30, 2013. The increase
      in the cash balance reflects financings completed in October 2013 and
      February 2014, plus cash inflow from exercise of warrants and stock
      options of $12.4 million.
    </p>
    <p>
      Common shares outstanding at June 30, 2014, were 52.9 million, and 58.5
      million assuming conversion of preferred stock outstanding.
    </p>
    <p>
      <b>Conference Call and Webcast Details</b>
    </p>
    <p>
      To participate in the conference call, please dial 855-215-6159 (toll
      free from the US) or 315-625-6887 (for international callers) and enter
      Conference ID 82825377. Investors may also access a live audio webcast
      of this conference call on the Company's website at <u>http://ir.arrowheadresearch.com/events.cfm</u>.
    </p>
    <p>
      A replay of the webcast will be available approximately two hours after
      the conclusion of the call and will remain available for 90 days. An
      audio replay will also be available approximately two hours after the
      conclusion of the call and will be available for 7 days. The audio
      replay can be accessed by dialing 855-859-2056 (toll free from the US),
      or 404-537-3406 (for international callers) and entering Conference ID
      82825377.
    </p>
    <div style="margin-left: 0pt; margin-right: 0pt; text-indent: 0pt; margin-bottom: 10pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>About ARC-520</b>
    </p>
    <p>
      Arrowhead&#8217;s RNAi-based candidate ARC-520 is designed to treat chronic
      HBV infection by reducing the expression and release of new viral
      particles and key viral proteins. The goal is to achieve a functional
      cure, which is an immune clearant state characterized by hepatitis B
      s-antigen negative serum with or without sero-conversion. The siRNAs in
      ARC-520 intervene at the mRNA level, upstream of where nucleotide and
      nucleoside analogues act. In transient and transgenic mouse models of
      HBV infection, a single co-injection of Arrowhead&#8217;s Dynamic
      Polyconjugate (DPC) delivery vehicle with cholesterol-conjugated siRNA
      targeting HBV sequences resulted in multi-log knockdown of HBV RNA,
      proteins and viral DNA with long duration of effect. The company is
      conducting a single dose Phase 2a study in chronic HBV patients, and
      expects to follow with a multi-dose, multi-national Phase 2b program.
      Approximately 350 million people worldwide are chronically infected with
      the hepatitis B virus. Chronic HBV infection can lead to cirrhosis of
      the liver and is responsible for 80% of primary liver cancers globally.
    </p>
    <p>
      <b>About ARC-AAT</b>
    </p>
    <p>
      Arrowhead has developed ARC-AAT for the treatment of liver disease
      associated with Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic
      disease that severely damages the liver and lungs of affected
      individuals. ARC-AAT employs a novel unlocked nucleobase analog (UNA)
      containing RNAi molecule designed for systemic delivery using the
      Dynamic Polyconjugate delivery system. ARC-AAT is highly effective at
      knocking down the Alpha-1 antitrypsin (AAT) gene transcript and reducing
      the hepatic production of mutant AAT (Z-AAT) protein. Reduction of
      inflammatory Z-AAT protein, which has been clearly defined as the cause
      of progressive liver disease in AATD patients, is important as it is
      expected to halt the progression of liver disease and allow fibrotic
      tissue repair. The Company plans to file for regulatory permission in
      the fourth quarter of 2014 and to commence clinical studies.
    </p>
    <p>
      <b>About Arrowhead Research Corporation</b>
    </p>
    <p>
      Arrowhead Research Corporation is a biopharmaceutical company developing
      targeted RNAi therapeutics. The company is leveraging its proprietary
      Dynamic Polyconjugate delivery platform to develop targeted drugs based
      on the RNA interference mechanism that efficiently silences
      disease-causing genes. Arrowhead&#8217;s pipeline includes ARC-520 for chronic
      hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1
      antitrypsin deficiency, and partner-based programs in obesity and
      oncology.
    </p>
    <p>
      For more information please visit <u>http://www.arrowheadresearch.com</u>,
      or follow us on Twitter @ArrowRes. To be added to the Company's email
      list to receive news directly, please send an email to <u>ir@arrowres.com</u>
    </p>
    <p>
      <b>Safe Harbor Statement under the Private Securities Litigation Reform
      Act:</b>
    </p>
    <p>
      <i>This news release contains forward-looking statements within the
      meaning of the &quot;safe harbor&quot; provisions of the Private Securities
      Litigation Reform Act of 1995. These statements are based upon our
      current expectations and speak only as of the date hereof. Our actual
      results may differ materially and adversely from those expressed in any
      forward-looking statements as a result of various factors and
      uncertainties, including our ability to finance our operations, the
      future success of our scientific studies, our ability to successfully
      develop drug candidates, the timing for starting and completing clinical
      trials, rapid technological change in our markets, and the enforcement
      of our intellectual property rights. Arrowhead Research Corporation's
      most recent Annual Report on Form 10-K and subsequent Quarterly Reports
      on Form 10-Q discuss some of the important risk factors that may affect
      our business, results of operations and financial condition. We assume
      no obligation to update or revise forward-looking statements to reflect
      new events or circumstances.</i>
    </p>
    <p>

    </p>
    <p>
      CONTACT:<br>Arrowhead Research Corporation<br>Vince Anzalone, CFA<br>626-304-3400<br><u>ir@arrowres.com</u><br>or<br><b>Investor
      Relations:</b><br>The Trout Group<br>Lauren Glaser<u><br></u>646-378-2972<br><u>ir@arrowres.com</u><br>or<br><b>Media:</b><br>Russo
      Partners<br>Martina Schwarzkopf, Ph.D.<u><br></u>212-845-4292<br><u>martina.schwarzkopf@russopartnersllc.com</u>
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
